Iain joined SV as a Venture Partner in 2022 and is the Chief Scientific Officer of SV portfolio company Sitryx Therapeutics.
Iain has over 25 years of global biopharmaceutical industry experience leading programmes from idea through to clinical development across a range of indications and therapeutic modalities. He developed as a drug discoverer during a 22-year tenure at Pfizer, starting as an internal industrial postdoc and taking on roles of increasing responsibility working across the drug discovery paradigm from target identification to leading the early clinical cluster in Rheumatology and Dermatology. Ultimately Iain served as Vice President Preclinical Sciences in the Inflammation and Immunology Research Unit, where he was responsible for a portfolio of both small and large molecule programmes targeted across rheumatology, dermatology and gastroenterology.
Iain left Pfizer at the end of 2018 to join Atlas Venture where he was the Chief Scientific Officer of Quench Bio whilst also working as an Entrepreneur in Residence across the Atlas portfolio.
Academic Credentials
Iain graduated with a BA and MA Cantab in Biochemistry from Jesus College, University of Cambridge, UK, before completing his PhD in the Breast Cancer Research Laboratories at the University of Liverpool, UK.
